mart-1-antigen has been researched along with Smooth-Muscle-Tumor* in 2 studies
1 review(s) available for mart-1-antigen and Smooth-Muscle-Tumor
Article | Year |
---|---|
Malignant perivascular epithelioid cell tumor involving the prostate.
Perivascular epithelioid cell tumor (PEComa) is a neoplasm chiefly composed of HMB-45-positive epithelioid cells with clear-to-granular cytoplasm and a perivascular distribution. We describe such a tumor involving the prostate and seminal vesicle in a 46-year-old man. The tumor had characteristic histologic features of PEComa. Immunohistochemically, the tumor cells were positive for HMB-45 but negative for epithelial markers, Melan-A, and S100 protein. The tumor behaved in a malignant fashion, and the patient died of the disease 4 years after diagnosis. Topics: Antigens, Neoplasm; Biomarkers, Tumor; Epithelioid Cells; Humans; Immunohistochemistry; Male; MART-1 Antigen; Melanoma-Specific Antigens; Middle Aged; Neoplasm Proteins; Prostatic Neoplasms; S100 Proteins; Seminal Vesicles; Smooth Muscle Tumor; Vascular Neoplasms | 2003 |
1 other study(ies) available for mart-1-antigen and Smooth-Muscle-Tumor
Article | Year |
---|---|
PNL2: A Useful Adjunct Biomarker to HMB45 in the Diagnosis of Uterine Perivascular Epithelioid Cell Tumor (PEComa).
Perivascular epithelioid cell tumors (PEComa) are rare neoplasms characterized by co-expression of melanocytic and muscle markers. HMB45 and Melan-A are used to confirm a PEComa diagnosis; however, both are often focally expressed and sensitivity for Melan-A is low. PNL2 is a reliable biomarker for epithelioid melanoma and renal angiomyolipoma/PEComa. The objective of this study was to determine PNL2 utility in diagnosing uterine PEComas as well as distinguishing PEComas from uterine smooth muscle tumors (SMTs). Twenty-one uterine PEComas and 45 SMTs were analyzed for PNL2; a subset was also stained for HMB45, Melan-A, Cathepsin-K, Desmin, and h-Caldesmon. Cases were scored as negative (0), focal (<10% of tumor cells), or patchy to diffusely positive (>10% of tumor cells). PEComas were positive for PNL2, HMB45, and Melan-A in 86%, 100%, and 57% of cases, respectively. In PEComas, PNL2 was patchy to diffusely positive more frequently (10/18, 56%) than Melan-A (4/12, 33%). In contrast, 2 of 45 (4%) SMTs were focally PNL2 positive; HMB45 was focally positive in 4 SMTs (11%) and all were negative for Melan-A. Desmin and h-Caldesmon were positive in 90% and 57% of PEComas, and 91% and 82% of SMTs. Cathepsin-K was positive in 100% of PEComas and 93% of SMTs. PNL2 is a useful biomarker for the diagnosis of uterine PEComa, with comparable sensitivity and specificity to HMB45. In contrast, PNL2 stains more PEComas when compared with Melan-A. Cathepsin-K, Desmin, and h-Caldesmon are of little utility for distinguishing PEComas and SMTs; however, lack of Cathepsin-K argues against PEComa. These results suggest that PNL2 should be used in conjunction with HMB45 in the diagnosis of PEComa of the uterine corpus. Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Biomarkers, Tumor; Female; gp100 Melanoma Antigen; Humans; Immunohistochemistry; MART-1 Antigen; Melanoma-Specific Antigens; Perivascular Epithelioid Cell Neoplasms; Receptors, Somatostatin; Smooth Muscle Tumor; Uterine Neoplasms | 2020 |